MetaVia Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
545 CONCORD AVENUE, CAMBRIDGE, MA, 02138
Mailing Address
545 CONCORD AVENUE, CAMBRIDGE, MA, 02138
Phone
(857) 702-9600
Fiscal Year End
1231
EIN
472389984
Financial Overview
FY2025
-$12.97M
Net Income
$16.68M
Stockholders' Equity
$-7.35
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
| 8-K Current report of material events | January 27, 2026 | View on SEC |
| 424B4 Prospectus for IPO or offering | January 16, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
| S-1/A IPO registration amendment | January 12, 2026 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Phase 2a study for vanoglipel demonstrated significant reduction in liver fat and improved blood sugar control.
- Phase 1 results for DA-1726 showed a 9.1% body weight loss over 56 days with a focus on muscle preservation.
Material Events
8-K
Financial Distress
December 19, 2025
High Impact
- MetaVia Inc. has successfully regained compliance with Nasdaq's minimum stock price requirement.
- The company received official notification from Nasdaq on December 19, 2025, confirming its stock price remained above $1.00 for 10 consecutive business days.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.